On the recordNovember 18, 2013
The issue for this committee is how the FDA seeks to regulate in this space and what that means to patients and innovators both now and in the future.
Source
congress.govEditor's note · Context
Upton discusses the implications of FDA regulation on patients and innovators.
Share
More from Fred Upton
Oct 19, 2021
I also want to highlight Representative Walberg and Tonko's Lead Poisoning Act, which I have cosponsored.
Jun 22, 2022
This bill, ARPA-H, can provide the breakthroughs necessary to find cures for those diseases. The President has already signed $1 billion for this program into law. So what we need now is bipartisan authorization to complete the work. This…
Oct 19, 2021
I want to really thank you also for looking at the Protecting Access to Lifesaving Screening, the PALS Act.
Other voices in this conversation
